Skip to main content
Autobound logo

Johnson & Johnson news in 2026: 28 dated events

The latest Johnson & Johnson event on this page is dated Oct 28, 2026. globenewswire.com reported: RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancer.

Public (JNJ)Pharmaceutical Manufacturing10,000+ employeesjnj.comLinkedIn

Get Johnson & Johnson's live signals in Claude or ChatGPT, or by API

Add to Claude / ChatGPT (MCP)Get an API key: 1,000 free credits
AskWhat changed at Johnson & Johnson this week? Use Autobound signals for jnj.com.
Dated events
28
Last 90 days
27
Latest
Oct 28, 2026

Source: Autobound Signal API · 86 signals tracked for Johnson & Johnson · updated

News · latest 10

Latest Johnson & Johnson news

  1. In development
    RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancerJohnson & Johnson released results from the Phase 1b/2 OrigAMI-4 study and expanded the clinical development of subcutaneous RYBREVANT (amivantamab) for head and neck cancer.
    globenewswire.com
  2. In development
    RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancerJohnson & Johnson is developing subcutaneous amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO) in ongoing Phase 1b/2 and Phase 3 clinical studies for advanced head and neck cancer.
    prnewswire.com
  3. In development
    Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancerJohnson & Johnson announced Phase 3 PROTEUS substudy results evaluating the investigational use of ERLEADA (apalutamide) plus androgen deprivation therapy before and after surgery in high-risk prostate cancer.
    prnewswire.com
  4. Spin-off
    Smith & Nephew talks with J&J on orthopaedics deal fail over CEO role, source saysWith DePuy Synthes
    wincountry.com
  5. In development
    New TREMFYA® (guselkumab) study shows consistent perianal fistula remission across key Crohn's disease patient subgroupsJohnson & Johnson announced new Phase 3 data from the FUZION study evaluating TREMFYA (guselkumab) for Crohn's disease patients with perianal fistula.
    prnewswire.com
  6. In development
    New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis2 stories
    prnewswire.com
  7. Launch
    A new modeled analysis strengthens the potential of TECVAYLI®▼ (teclistamab) combined with daratumumab to redefine long-term survival prospects in relapsed/refractory multiple...Johnson & Johnson announced new data from its Phase 3 MajesTEC-3 study for TECVAYLI® (teclistamab) combined with daratumumab, showing durable disease control and prolonged survival in patients with relapsed or refractory multiple myeloma.
    globenewswire.com
  8. In development
    Johnson & Johnson announces TREMFYA® (guselkumab) is the first and only IL-23 inhibitor to show significant improvement in spinal pain and stiffness in landmark axial psoriatic...Johnson & Johnson announced its drug TREMFYA® (guselkumab) met primary and major secondary endpoints in its Phase 4 STAR study for treating adults with active psoriatic arthritis and axial involvement.
    prnewswire.com
  9. In development
    New model-based analysis further supports the potential of TECVAYLI® (teclistamab-cqyv) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) to redefine long-term...Johnson & Johnson announced new data from the Phase 3 MajesTEC-3 study for its combination therapy of TECVAYLI® and DARZALEX FASPRO® for relapsed or refractory multiple myeloma, showing sustained disease control and survival.
    prnewswire.com
  10. Launch
    European Commission approval of ICOTYDE™▼(icotrokinra) ushers in new era for first-line systemic treatment of plaque psoriasis with a targeted oral peptide2 stories
    globenewswire.com

Showing 10 of 28 dated events. The Signal API returns all of them.

Get them with one API call

Signal API · MCP

Track Johnson & Johnson with the Signal API

One POST /v1/companies/enrich call with jnj.com returns Johnson & Johnson news signals (news), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"jnj.com","signal_types":["news"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real News records, as a CSV.

Talk to sales

Same industry

News at related companies

Questions about Johnson & Johnson news

What is the latest news on Johnson & Johnson?
The newest event on this page is dated Oct 28, 2026. globenewswire.com reported: RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancer. This page lists 28 dated events for Johnson & Johnson, each with a source link.
What is going on with Johnson & Johnson?
The 10 latest events on this page cover in development (7), spin-off (1) and launch (2). The newest: Oct 28, 2026: RYBREVANT®▼ (amivantamab) subcutaneous demonstrates a 77 percent objective response rate in first-line treatment for patients with certain advanced forms of head and neck cancer (globenewswire.com).
Is Johnson & Johnson laying off employees?
1 layoff event was reported for Johnson & Johnson. The latest: Sep 21, 2026: Johnson & Johnson Stock Reacts to New Earnings Estimates and Job Cut Signal (ad-hoc-news.de). See the Johnson & Johnson layoffs page for the dated list.

Page updated , the date of the newest row on this page.

Source. News articles about the company, one source link per event.

Method. Stories about the same event within 14 days merge into one row. Noise (lists, stock tips, recaps) is removed.

Data as of .

How this data is built →Get it from the Signal API →